# Vyne Therapeutics Inc. (VYNE)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $28M  
**Price:** $0.66 (+0.93%)

> Vyne Therapeutics Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative dermatology solutions. Primarily focused on the treatment of skin diseases, Vyne Therapeutics leverages its proprietary technologies to address conditions such as acne and rosacea. The company's commitment to advancing dermatological research is evident in its pipeline of therapeutic products that aim to enhance the care and management of skin conditions. By working closely with healthcare professionals and leveraging partnerships within the pharmaceutical industry, Vyne Therapeutics strives to deliver effective treatment options that improve patient outcomes. As an active participant in the biopharmaceutical market, Vyne Therapeutics plays a critical role in advancing dermatological therapies, contributing to the broader medical and healthcare sectors by providing solutions that benefit consumers and practitioners alike.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $570,000 | — | -$30M | -$26M | — |
| 2024 | $501,000 | — | -$44M | -$40M | — |
| 2023 | $424,000 | — | -$29M | -$28M | — |
| 2022 | $477,000 | — | -$34M | -$23M | — |
| 2021 | $931,000 | — | -$39M | -$73M | — |
| 2020 | $21M | — | -$253M | -$256M | — |
| 2019 | $443,000 | — | -$96M | -$95M | — |
| 2018 | $4M | — | -$75M | -$74M | — |
| 2017 | $5M | — | -$30M | -$29M | — |
| 2016 | $674,000 | — | -$14M | -$14M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $30M | $2M | $28M | $24M | — |
| 2024 | $67M | $15M | $52M | $20M | — |
| 2023 | $98M | $9M | $89M | $31M | — |
| 2022 | $41M | $9M | $31M | $31M | — |
| 2021 | $67M | $18M | $49M | $42M | — |
| 2020 | $94M | $56M | $37M | $58M | $33M |
| 2019 | $81M | $64M | $18M | $44M | $33M |
| 2018 | $140M | $10M | $92M | $28M | — |
| 2017 | $67M | $15M | $69M | $10M | — |
| 2016 | $42M | $12M | -$29M | $4M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$33M | — | — |
| 2024 | -$34M | — | — |
| 2023 | -$25M | — | — |
| 2022 | -$29M | — | — |
| 2021 | -$56M | — | -$56M |
| 2020 | -$137M | $113,000 | -$137M |
| 2019 | -$73M | $1M | -$74M |
| 2018 | -$69M | $567,000 | -$69M |
| 2017 | -$28M | $27,000 | -$28M |
| 2016 | -$2M | $31,000 | -$2M |
| 2015 | -$4M | — | -$4M |

Source: [CompaniesByCap](https://companiesbycap.com/company/VYNE)